BMEA
Price
$3.46
Change
-$0.19 (-5.21%)
Updated
Feb 21 closing price
Capitalization
125.39M
9 days until earnings call
RXRX
Price
$9.28
Change
-$1.08 (-10.43%)
Updated
Feb 21, 04:59 PM (EDT)
Capitalization
3.62B
10 days until earnings call
Ad is loading...

BMEA vs RXRX

Header iconBMEA vs RXRX Comparison
Open Charts BMEA vs RXRXBanner chart's image
Biomea Fusion
Price$3.46
Change-$0.19 (-5.21%)
Volume$294.08K
Capitalization125.39M
Recursion Pharmaceuticals
Price$9.28
Change-$1.08 (-10.43%)
Volume$218.1K
Capitalization3.62B
BMEA vs RXRX Comparison Chart
Loading...
BMEA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMEA vs. RXRX commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMEA is a Hold and RXRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (BMEA: $3.65 vs. RXRX: $10.35)
Brand notoriety: BMEA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMEA: 29% vs. RXRX: 163%
Market capitalization -- BMEA: $125.39M vs. RXRX: $3.62B
BMEA [@Biotechnology] is valued at $125.39M. RXRX’s [@Biotechnology] market capitalization is $3.62B. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMEA’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • BMEA’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, RXRX is a better buy in the long-term than BMEA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMEA’s TA Score shows that 6 TA indicator(s) are bullish while RXRX’s TA Score has 7 bullish TA indicator(s).

  • BMEA’s TA Score: 6 bullish, 2 bearish.
  • RXRX’s TA Score: 7 bullish, 4 bearish.
According to our system of comparison, BMEA is a better buy in the short-term than RXRX.

Price Growth

BMEA (@Biotechnology) experienced а +1.11% price change this week, while RXRX (@Biotechnology) price change was +21.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

BMEA is expected to report earnings on Apr 30, 2025.

RXRX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($3.62B) has a higher market cap than BMEA($125M). RXRX YTD gains are higher at: 53.107 vs. BMEA (-5.928). BMEA has higher annual earnings (EBITDA): -149.62M vs. RXRX (-350.86M). RXRX has more cash in the bank: 428M vs. BMEA (88M). BMEA has less debt than RXRX: BMEA (9.57M) vs RXRX (90.6M). RXRX has higher revenues than BMEA: RXRX (64.6M) vs BMEA (0).
BMEARXRXBMEA / RXRX
Capitalization125M3.62B3%
EBITDA-149.62M-350.86M43%
Gain YTD-5.92853.107-11%
P/E RatioN/AN/A-
Revenue064.6M-
Total Cash88M428M21%
Total Debt9.57M90.6M11%
TECHNICAL ANALYSIS
Technical Analysis
BMEARXRX
RSI
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
83%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 27 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
89%
View a ticker or compare two or three
Ad is loading...
BMEA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EUGDX28.72N/A
N/A
Morgan Stanley Europe Opportunity I
VTSMX147.49N/A
N/A
Vanguard Total Stock Mkt Idx Inv
GRGRX48.02N/A
N/A
Goldman Sachs Equity Income R
FEIFX32.98N/A
N/A
Franklin Equity Income Adv
TICSX7.16-0.09
-1.24%
Touchstone Small Company Instl

BMEA and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMEA has been loosely correlated with ARCT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BMEA jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMEA
1D Price
Change %
BMEA100%
+2.24%
ARCT - BMEA
50%
Loosely correlated
-2.31%
KROS - BMEA
31%
Poorly correlated
+3.96%
PYXS - BMEA
29%
Poorly correlated
+0.74%
ABOS - BMEA
29%
Poorly correlated
-1.43%
RXRX - BMEA
29%
Poorly correlated
-4.78%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-4.78%
CRSP - RXRX
64%
Loosely correlated
-4.88%
BEAM - RXRX
58%
Loosely correlated
-2.79%
PRME - RXRX
53%
Loosely correlated
-4.72%
NTLA - RXRX
51%
Loosely correlated
-0.24%
AXON - RXRX
49%
Loosely correlated
-8.70%
More